BIOFIRE BCID2 Blood Culture Panel Recalled for False Negatives: Health Canada

Health Canada has published a Type II health product recall covering one lot of the BIOFIRE Blood Culture Identification 2 (BCID2) Panel, a medical device used in the chemistry testing category. The notice, posted on October 28, 2026, says the manufacturer has linked the lot to an elevated risk of false negative results. The recall itself is dated October 21, 2026, and is tracked under identification number RA-82873.

The recall is aimed at healthcare audiences rather than the general public. The affected product is the BIOFIRE Blood Culture Identification 2 (BCID2), 30-Pack, made by Biofire Diagnostics, LLC.

• Product: BIOFIRE Blood Culture Identification 2 (BCID2), 30-Pack
• Kit lot: 0727226
• Pouch lot: 3ZQT26
• Model or catalogue number: RFIT-ASY-0147
• Recall class: Type II
• Recall number: RA-82873
• Issue: Medical devices – Performance

Products Affected by This Recall

Only one product and one lot are named in the Health Canada notice. The affected item is the BIOFIRE BCID2 Panel 30-Pack, kit lot 0727226, which corresponds to pouch lot 3ZQT26. The catalogue number listed is RFIT-ASY-0147.

The notice states that no other BIOFIRE product lots were determined to be impacted. The number of units distributed in Canada is not given in the source.

What Triggered the Recall

According to the notice, BioMérieux received complaints of false negative results on BIOFIRE BCID2 Panel kit lot 0727226 and pouch lot 3ZQT26. An investigation then identified a product issue.

The problem is described as unintended movement of pouch chemistry in the affected kit lot. Based on the investigation, this movement can lead to an elevated risk of false negative results. The notice adds that all analytes on the panel may be at risk of producing false negative results, so the concern is not limited to a single target on the panel.

The action is described as a field safety notice. The notice does not say how many complaints were received or whether any patient harm has been reported.

Why a False Negative Matters

A false negative on a diagnostic panel means a test may fail to detect something that is actually present in a sample. The panel in question is a blood culture identification product, which is used in a healthcare setting. The Health Canada notice does not describe specific patient outcomes, and this article does not speculate beyond the source. It confirms only that the manufacturer’s investigation found an elevated risk of false negative results for this lot.

Who Should Be Concerned

The audience listed for this recall is Healthcare. That points to laboratories, hospitals and other facilities that may hold or use the affected BIOFIRE BCID2 kit. The product is a professional medical device, and it is not sold to consumers in the way household goods are.

The Health Canada notice lists Biofire Diagnostics, LLC, of Salt Lake City, Utah, as the company. The recall is published under the Health Canada Medical devices program.

How to Respond to This Recall

The only action Health Canada lists is to contact the manufacturer if you require additional information. The notice does not provide a phone number or email address, so readers should use the manufacturer’s regular channels or the official recall page.

• Check whether your facility holds BIOFIRE BCID2 30-Pack kit lot 0727226, pouch lot 3ZQT26, catalogue number RFIT-ASY-0147.
• Contact the manufacturer if you need more information about the field safety notice.
• Use the Government of Canada recall page to confirm the latest details.

Regulatory Response

Health Canada classified this action as a Type II recall and published it on its Recalls and Safety Alerts site on October 28, 2026. The notice lists the issue as a medical device performance problem and names BioMérieux as the party that received the complaints. Health Canada’s description says that based on the investigation, the unintended movement of pouch chemistry can lead to an elevated risk of false negative results.

Anyone who wants to report a health or safety concern about a product can use the reporting link provided on the Health Canada page. Updates to this recall will appear on the official recall listing, and readers can also subscribe to Health Canada email notifications for new and updated alerts.

This article reflects only what is stated in the 2026 Health Canada notice, and no additional lots, distribution figures or patient outcomes have been reported in that source.